Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 2
2013 2
2014 2
2015 3
2016 7
2017 5
2018 5
2019 3
2020 2
2021 3
2022 3
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors.
Nakaue E, Teramachi J, Tenshin H, Hiasa M, Harada T, Oda A, Inoue Y, Shimizu S, Higa Y, Sogabe K, Oura M, Hara T, Sumitani R, Maruhashi T, Yamagami H, Endo I, Tanaka E, Abe M. Nakaue E, et al. Among authors: teramachi j. Int J Hematol. 2023 Jul;118(1):88-98. doi: 10.1007/s12185-023-03601-2. Epub 2023 Apr 11. Int J Hematol. 2023. PMID: 37039914 Free PMC article.
Mechanical unloading aggravates bone destruction and tumor expansion in myeloma.
Tanimoto K, Hiasa M, Tenshin H, Teramachi J, Oda A, Harada T, Higa Y, Sogabe K, Oura M, Sumitani R, Hara T, Endo I, Matsumoto T, Tanaka E, Abe M. Tanimoto K, et al. Among authors: teramachi j. Haematologica. 2022 Mar 1;107(3):744-749. doi: 10.3324/haematol.2021.278295. Haematologica. 2022. PMID: 34788982 Free PMC article. No abstract available.
Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase.
Harada T, Ohguchi H, Oda A, Nakao M, Teramachi J, Hiasa M, Sumitani R, Oura M, Sogabe K, Maruhashi T, Takahashi M, Fujii S, Nakamura S, Miki H, Kagawa K, Ozaki S, Sano S, Hideshima T, Abe M. Harada T, et al. Among authors: teramachi j. Blood Adv. 2023 Mar 28;7(6):1019-1032. doi: 10.1182/bloodadvances.2022007155. Blood Adv. 2023. PMID: 36129197 Free PMC article.
The Xanthine Oxidase Inhibitor Febuxostat Suppresses Adipogenesis and Activates Nrf2.
Higa Y, Hiasa M, Tenshin H, Nakaue E, Tanaka M, Kim S, Nakagawa M, Shimizu S, Tanimoto K, Teramachi J, Harada T, Oda A, Oura M, Sogabe K, Hara T, Sumitani R, Maruhashi T, Yamagami H, Endo I, Matsumoto T, Tanaka E, Abe M. Higa Y, et al. Among authors: teramachi j. Antioxidants (Basel). 2023 Jan 5;12(1):133. doi: 10.3390/antiox12010133. Antioxidants (Basel). 2023. PMID: 36670994 Free PMC article.
Therapeutic efficacy of the resorcylic acid lactone LL-Z1640-2 for adult T-cell leukaemia/lymphoma.
Oura M, Harada T, Oda A, Teramachi J, Nakayama A, Sumitani R, Inoue Y, Maeda Y, Sogabe K, Maruhashi T, Takahashi M, Fujii S, Nakamura S, Miki H, Nakamura M, Hara T, Yamagami H, Kurahashi K, Endo I, Hasegawa H, Fujiwara H, Abe M. Oura M, et al. Among authors: teramachi j. EJHaem. 2023 Jul 27;4(3):667-678. doi: 10.1002/jha2.758. eCollection 2023 Aug. EJHaem. 2023. PMID: 37601887 Free PMC article.
Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma.
Teramachi J, Hiasa M, Oda A, Harada T, Nakamura S, Amachi R, Tenshin H, Iwasa M, Fujii S, Kagawa K, Miki H, Kurahashi K, Yoshida S, Endo I, Haneji T, Matsumoto T, Abe M. Teramachi J, et al. Br J Haematol. 2018 Feb;180(4):581-585. doi: 10.1111/bjh.14388. Epub 2016 Oct 17. Br J Haematol. 2018. PMID: 27748523 Free article. No abstract available.
Osteoclast-derived IGF1 is required for pagetic lesion formation in vivo.
Miyagawa K, Ohata Y, Delgado-Calle J, Teramachi J, Zhou H, Dempster DD, Subler MA, Windle JJ, Chirgwin JM, Roodman GD, Kurihara N. Miyagawa K, et al. Among authors: teramachi j. JCI Insight. 2020 Mar 26;5(6):e133113. doi: 10.1172/jci.insight.133113. JCI Insight. 2020. PMID: 32078587 Free PMC article.
40 results